Impact Analysis of Covid-19
The complete version of the REPORT will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.
Summary
The global Integrin Alpha 4 Market is expected to witness a CAGR of xx% over the forecast period 2020-2026 and is expected to reach US$ xx million in 2026, from US$ xx million in 2019.
The regulation of integrin alpha 4 activity is still under development, but recent advances in the field have indicated that it may be important for therapeutic intervention. Moreover, the side chains of selected b1 units have been indicated. Thus, future studies will help identify the optimal targets for novel agents. This in turn could lead to the development of new therapies for various etiologies that currently lack treatment. Human ITGA4 is a gene that encodes a subunit of the integrin alpha family. Integrin Alpha 4 beta 1 is expressed in leukocytes and regulates the migration of immune cells. It also interacts with other adhesion molecules and binds to JAM-B expressed on endothelial cells to facilitate transendothelial migration.
Drivers
The global integrin alpha 4 market is projected to expand at a faster rate than the overall market due to factors such as the high adoption of stem cell therapies for cell retention and engraftment across the healthcare sector.
Furthermore, the increasing use of these inhibitors in regulating the homing of endothelial progenitor cells to areas of ischemia to promote neovascularization is expected to boost the growth of the global integrin alpha 4 market during the forecast period. For instance, in February 2021, Morphic Therapeutics, a major biopharmaceutical firm focused on developing oral integrin therapies, showcased its MORF-057, a small molecule development candidate for the treatment of inflammatory bowel disease.
Restraints
Stringent approval pathways for biosimilars and poor understanding of this mechanism are expected to limit the growth of the global integrin alpha 4 market.
Regional Insights
On the basis of geography, the North American area is in the driver's seat for the global integrin alpha 4 market, owing to the high expenditure on the healthcare sector and increasing cases of life-threatening injuries.
Another important geographic area driving the global integrin alpha 4 market in the Asia Pacific, is benefiting from the increasing prominence of stem cell therapies and their growing application in developing cancer immunotherapies.
Competitive Landscape
- Major companies contributing to the global integrin alpha 4 market include EA Pharma Co., Ltd., Daiichi Sankyo Co., Ltd., Biogen, Inc., Protagonist Therapeutics, Inc., Amgen, Inc., Viriom, Inc., Antisense Therapeutics Ltd., Takeda Pharmaceutical Co., Ltd., BioMAS Ltd., Morphic Therapeutics, Inc., and Immunwork, Inc.
- In April 2022, Protagonist Therapeutics revealed the results of its Phase II clinical study on ulcerative colitis, concluding that PN-943 achieved 27% clinical remission in a twice-a-day dose.
The Integrin Alpha 4 Market report highlights product development and growth strategies such as mergers and acquisitions adopted by market players along with SWOT Analysis, PEST and Porter’s Five Forces analyses of the Integrin Alpha 4 Market, which highlight the strengths, weaknesses, opportunities, and commination of key companies. Moreover, the report offers two distinct market forecasts, one from the perspective of the producer and another from that of the consumer.
The various contributors involved in the value chain of the product include manufacturers, suppliers, distributors, intermediaries, and customers.
The Key Manufacturers covered in this Report:-
- Amgen Inc
- Antisense Therapeutics Ltd
- Biogen Inc
- BioMAS Ltd
- Daiichi Sankyo Co Ltd
- EA Pharma Co Ltd
- Immunwork Inc
- Morphic Therapeutic Inc
- Protagonist Therapeutics Inc
- Takeda Pharmaceutical Co Ltd
- Viriom Inc
By the Product Type, the market is primarily segmented into:
- TE-5232
- ATL-1102
- Carotegrast
- ET-3764
- Others
By Applications, the market is segmented into:
- Acute Ischemic Stroke
- Celiac Disease
- Epilepsy
- Melanoma
- Multiple Sclerosis
- Other
The Report covers the following Regions:
- North America
- United States
- Canada
- Mexico
- Asia Pacific
- China
- Japan
- South Korea
- India
- Australia
- Indonesia
- Thailand
- Malaysia
- Philippines
- Vietnam
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Central & South America
- Middle East & Africa
- Turkey
- GCC Countries
- Egypt
- South Africa
Objective of the Integrin Alpha 4 Market Report:
- To assess the size of the market by value and volume
- Analyze the Integrin Alpha 4 Market in terms of regions and major countries
- Highlight recent developments and trends in the market
- Offer perceptive data regarding major market players in terms of key developments, strategies, and product portfolio
- Determine share of the Integrin Alpha 4 Market in terms of various segments such as by product type, application, and end-user
- Offer accurate projection of the market for the forecast period using state–of–the–art tools and the current primary and secondary research approaches
- Discuss major factors that impact growth of the Integrin Alpha 4 Market
The Integrin Alpha 4 Market engages the readers with all pivotal approaches to understand their position in the industry based on revenue or sales growth. The report efficiently evaluates the Integrin Alpha 4 Market from various dimensions to deliver an end-product that is informative, elaborate, and accurate and includes detailed market segmentation, regional analysis, and competition in the market. The information in the report is backed by annual company reports, financial reports, press releases, regulatory databases, government documents, and statistical databases.
For the data information by region, company, type and application, 2019 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
Key Stakeholders:
- Material suppliers/wholesalers
- Market Distributors/traders
- Regulatory bodies
- Research organizations, and consulting firms
- Commercial research & developments (R&D)
- Trade associations and industry bodies
- Importers and exporters
- End-use industries
Available Customizations:
Custom research is one of the most crucial components of the business strategy that helps an organization gain insight into specific business sector, aligned with its specific area of interest. Thus, SMI offers more accurate, pragmatic, and actionable information specifically tailored to suit your business needs.
